Concomitant Oral Tyrosine Kinase Inhibitors and Bisphosphonates in Advanced Renal Cell Carcinoma With Bone Metastases

British Journal of Cancer- United Kingdom

doi 10.1038/bjc.2012.385

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Brain Metastases From Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors

Clinical Genitourinary Cancer
OncologyUrology
2013English

Complete Remission of Bone Metastases in Renal Cell Carcinoma With Nivolumab

Cureus
2019English

Bisphosphonates and Bone Metastases

British Journal of Cancer
Cancer ResearchOncology
1988English

Do Tyrosine Kinase Inhibitors Lose Favor in Treatment of First-Line Metastatic Renal Cell Carcinoma?

Future Oncology
MedicineCancer ResearchOncology
2019English

Cerebrovascular Ischemic Events in Patients With Advanced Renal Cell Carcinoma Treated With Anti-Angiogenic Tyrosine Kinase Inhibitors: A Report on Two Cases With Different Outcomes

Journal of Medical Cases
2015English

Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer

Journal of the Siena Academy of Sciences
2012English

Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients With Renal Cell Carcinoma

European Urology
Urology
2014English

Xp11.2�translocation Renal Cell Carcinoma With Multiple Bone Metastases: A Case Report

Oncology Letters
Cancer ResearchOncology
2016English

Personalized Therapy in Renal Cell Carcinoma: Are the Different Tyrosine Kinase Inhibitors the Same for Any Patient?

Expert Review of Precision Medicine and Drug Development
Molecular MedicineDrug DiscoveryGeneticsPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy